Dry Age Related Macular Degeneration

Overview of mild, moderate and severe dry AMD including drusen and geographic atrophy.

What are Drusen?

The hallmark of dry AMD is macular drusen (see photo). Drusen are made up of lipids, a type of fatty protein. They may be the result of a failure of the eye to dispose of waste products that are produced when the photoreceptors of the eye drop off older parts of the cell. There are several types of drusen with different levels of risk. Drusen can be small, hard and scattered far apart from each other. They are round and distinct. This type may not create vision problems for a long time and may not even be an indication of macular degeneration. Some drusen can become larger, softer and closer together. Their edges are less distinct. When they get to that stage, there is a greater risk for developing wet macular degeneration and more severe vision loss. They can also disrupt the layers of the retina and may lead to retinal pigment epithelium detachment (PED). Your doctor can see these drusen during a dilated eye exam, even if you are not aware of a vision change. That is one reason why regular eye exams are so important. If you have the larger, soft drusen, your doctor will probably want you to come into the office for check-ups more often. If they do lead to wet macular degeneration, early treatment is essential.

What is Geographic Atrophy?

Geographic atrophy occurs when the photoreceptors (seeing part of the retina) no longer works and the patient develops a blind spot or spot of poor vision in the macula (see photo). Geographic atrophy (GA) is considered the late stage of the dry form of Age-related Macular Degeneration (AMD). It only occurs in about 10 percent of dry AMD patients. GA is usually a sharply delineated round or oval area of hypopigmentation, or apparent absence of the retinal pigment epithelium (RPE), in which choroidal vessels are more visible than in surrounding areas The most common sequence of events leading to GA is the progression of a large drusen to hyperpigmentation, followed by regression of the drusen, hypopigmentation and ultimately RPE cell death, with development of an atrophic area of retina and underlying choriocapillaris, sometimes preceded by the appearance of refractile deposits. This usually takes more than 5 years. Less frequently, GA can follow a drusenoid RPE detachment, regression of a CNV membrane or a RPE rupture. As other forms of late AMD, GA tends to be bilateral (over 50% of cases) and there is high symmetry between eyes for total atrophic area, presence of peripapillary atrophy and enlargement rate. GA often first develops surrounding the fovea, sparing the central area.

What is Progressive Geographic Atrophy?

Geographic atrophy can progress and lead to vision loss. When people with dry AMD lose vision, it is almost always from geographic atrophy. The animated image with this text shows growing geographic atrophy over 3 years in an 86 year old patient. This person is fortunate to have good vision because the dark areas of geographic atrophy are not yet affecting the central vision. Given the progression, the central vision will likely be affected within about 10 years. The images are fundus autofluorescent images that are useful for following geographic atrophy because the atrophy shows up as well delineated dark spots.

What is Pattern Dystrophy?

Pattern dystrophy is a type of dry age-related macular degeneration that involves mostly the very center of the macula. There are several types of pattern dystrophy. The image with this text is of a patient with adult vitelliform macular dystrophy. The image shows the buildup of abnormal deposits under the retina in the center of the macula. Unlike typical dry macular degeneration where the buildup of material is below the retinal pigment epithelium, in pattern dystrophy, the buildup of material is above the pigment epithelium and directly beneath the retina (see asterisks on image). Pattern dysrophy is autosomal dominant, usually presents at a younger age than typical dry AMD, and usually does not progress to wet AMD.

Pattern Dystrophy

What about Diet?

Patients who consume fruits and vegetables have the lowest rates of macular degeneration development. Lutein, a carotenoid pigment found exclusively in fruit and vegetables, serves as the primary protector of the eye. Lutein accumulates in the macula and likely blocks the damage caused by sunlight, one proposed cause of AMD. Fruits and vegetables are also high in antioxidant vitamins such as Beta- carotene, Vitamin E, and Vitamin C. Green leafy vegetables and other colorful foods like kiwi, squash, red grapes, and corn are good sources of Lutein. Other dietary habits have been shown to increase the risk of AMD. Individuals with a higher percentage of vegetable, monounsaturated, and polyunsaturated fats in their diet have higher rates of Wet AMD development. Diets rich in Omega 3 fatty acids reduce the risk of vision loss. These are found naturally in cold-water fish such as salmon and tuna, and in flaxseeds and flaxseed oil. Two servings of fish per week are adequate.

What about Vitamins?

The Age-Related Eye Disease Study 2 showed that among people at high risk for developing late-stage, or wet, macular degeneration (such as those who have large amounts of drusen or who have significant vision loss in at least one eye), taking a dietary supplement of vitamin C, vitamin E, lutein and zeaxanthin, along with zinc, lowered the risk of macular degeneration progressing to advanced stages by at least 25 percent. The supplements did not appear to provide a benefit for people with minimal macular degeneration or people without evidence of the disease during the course of the study. These vitamins contain a mixture of Vitamins C and E, Lutein, Zeaxanthin, Zing and Copper. Another large study in women showed a benefit from taking folic acid and vitamins B6 and B12. It is very important to remember that vitamin supplements are not a cure for macular degeneration, nor will they give you back vision that you may have already lost from the disease. However, these supplements do play a key role in helping some people at high risk for developing advanced (wet) AMD to maintain their vision, or slow down the progression of the disease.

What about Amsler Grid?

One of the first signs of macular degeneration can be wavy, broken or distorted lines OR a blurred or missing area of vision. The Amsler Grid can help you spot these early. Early detection of wet AMD is critical because laser treatment, when indicated, is most successful when performed before damage occurs. Since dry AMD can lead to development of wet AMD, most patients should use the Amsler Grid. Check with your eye doctor to find out how often you should use this test. Wear your reading glasses, if you normally use them and sit about 14 inches away from the screen. Check one eye at a time. Cover the eye you are not testing. Focus on the dark dot in the center of the grid. While looking at this dot, you still should be aware of the lines of the grid. Notice if any of the lines are distorted or broken or if there are blurred areas.

Download Amsler Grid

Dry Macular Degeneration NEWS

Below are current articles from a Google News Feed on Dry Macular Degeneration

Belite Bio to trial new therapy for macular degeneration  Drug Development Technology

Belite Bio has received the US FDA approval to conduct a Phase I clinical trial of LBS-008 to treat dry macular degeneration and Stargardt disease.

Improving the Burden of Treatment for Age-related Macular Degeneration Through Advances in Delivery  Healio

Learning Objectives: Upon successful completion of this activity, participants should be better able to: Review the evidence regarding the visual effects of ...

FDA partially lifts clinical hold for Adverum's wet AMD gene therapy  Healio

The FDA has partially lifted the clinical hold on Adverum Biotechnologies' wet age-related macular degeneration gene therapy treatment candidate ADVM-022, ...

Aflibercept in the Context of AMD Treatment  MD Magazine

A review highlights aflibercept's efficacy in treatment non-responders and points to a couple promising new AMD therapies in development.

Diabetes Drug Metformin Associated with Reduced AMD Risk  MD Magazine

Metformin use associated with a 58% reduced risk of age-related macular degeneration (AMD) in a case-controlled retrospective study.

Wet Age-Related Macular Degeneration Market 2014-2024 by Product, Distribution Channel, Age Group, Route of Administration, & End User, - ResearchAndMarkets.com  Associated Press

Press release *content* from Business Wire. The AP news staff was not involved in its creation.

Eye in a Dish Takes Unblinking View of Macular Degeneration's Genetics  Genetic Engineering & Biotechnology News

Acute macular degeneration's genetic underpinnings revealed using a model of the retinal epithelium derived from induced pluripotent stem cells.

First patient recruited in global AMD trial  PharmaTimes

The new treatment involves stimulating cells in the retina with light in a process called 'photobiomodulation.' - News - PharmaTimes.

Technological advances, preventable strategies can help manage age-related macular degeneration  Reading Eagle

Age-related macular degeneration, or AMD, has long been a scourge for many people as they age.

Take care of your vision; get a thorough eye exam to detect problems early and protect your health  User-generated content

By age 65, one in three Americans will have a vision-impairing eye disease. Many sight-robbing conditions can be effectively treated if detected early enough, ...

Personalized “Eye-in-a-Dish” Models Reveal Genetic Underpinnings of Macular Degeneration  UC San Diego Health

Using stem cells derived from six people, UC San Diego School of Medicine researchers recapitulated retinal cells in the lab. This “eye-in-a-dish” model allowed ...

Pixium Vision and research partners to report clinical progress with the PRIMA bionic vision system during ARVO 2019 World Conference  GlobeNewswire

Paris, April 24th, 2019 – 7:00 CET - Pixium Vision (FR0011950641 - PIX), a bioelectronics company developing innovative bionic vision systems to enable ...

Global Wet Age Related Macular Degeneration (AMD) Market 2019 - Novartis International (Switzerland), Bayer (Germany), Acucela (US), Neurotech Pharmaceuticals (US), Ophthotech (US)  Industry Module

Wet Age Related Macular Degeneration (AMD) Market Report highlights current and future aspects of market analysis on the basis of changing trends of industry ...

Belite Bio Announces FDA Approval of Investigational New Drug (IND) for Phase 1 Clinical Trial of LBS-008 to Treat Macular Degeneration and Stargardt Disease  PRNewswire

SAN DIEGO, April 24, 2019 /PRNewswire/ -- Belite Bio, a drug development company targeting currently untreatable conditions in ophthalmology and metabolic ...

Outlook Therapeutics stock triples in three days after Oppenheimer offers $12 price target  Proactive Investors USA & Canada

Outlook Therapeutics (NASDAQ:OTLK) - Analysts at Oppenheimer saw potential in the development of its ONS-5010 treatment for various eye diseases.

Eye-in-a-Dish Models Reveal Genetic Underpinnings of Macular Degeneration  Technology Networks

Technology Networks is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters.

BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®  Associated Press

Press release *content* from Business Wire. The AP news staff was not involved in its creation.

Epigenetics May Help Explain Degrading Eyesight  WhatIsEpigenetics.com

As we get older, our bodies begin to wear out and lose the ability to function as well as they once did. We start to ache for no reason, our hearing isn't as ...

Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration  Yahoo Finance

Catalyst Biosciences, Inc. (CBIO), and Mosaic Biosciences today announced the presentation of new data on pegylated CB 2782 (CB 2782-PEG), Catalyst's ...

8 Nutrients That Will Optimize Your Eye Health  EcoWatch

Eye health goes hand-in-hand with general health, but a few nutrients are especially important for your eyes. These nutrients help maintain eye function, protect ...

Stealth Bio's elamipretide shows positive action in early-stage AMD study  Seeking Alpha

Results from an open-label Phase 1 clinical trial evaluating Stealth BioTherapeutics' (MITO) elamipretide in patients with dry age-related macular degenera.

What Is the Difference Between Wet or Dry Macular Degeneration?  University of Michigan Health System News

Dry macular degeneration occurs when cells of the macula begin to thin and break down. It is characterized by drusen buildup and typically worsens over time.

Stealth BioTherapeutics Announces Positive Results for Elamipretide in Ophthalmic Conditions  PRNewswire

BOSTON, April 30, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, ...

Discover the Growth of the Age-related Macular Degeneration Market with Leading Manufacturers Alcon, Allergan, Avalanche, Bausch+Lomb  MajoReports

A latest study released by HTF MI on Global (United States, European Union and China) Age-related Macular Degeneration Market covering key business ...

Stealth BioTherapeutics Reports First Quarter 2019 Financial Results And Recent Business Highlights  PRNewswire

BOSTON, May 15, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, ...

Vitamins, new treatments offer hope for people with macular degeneration  nwitimes.com

Macular degeneration is the leading cause of vision loss, affecting more than 10 million Americans — more than cataracts and glaucoma combined.

Outlook Therapeutics initiated with an Outperform rating, $12 price target at Oppenheimer  Proactive Investors USA & Canada

Outlook Therapeutics (NASDAQ:OTLK) - Shares in the biopharma doubled after Oppenheimer analyst Leland Gershell saw promise in the company's ONS-5010 ...

BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting  BioSpace

Treatment with OpRegen® Continues to be Well Tolerated with Signs of Structural Improvement in the Retina Observed in Some Patients. ALAMEDA, Calif.

Allegro Ophthalmics to Present the Results of Its ALG-1007 Ex-US Trial for Dry Eye Disease at the 2019 ASCRS•ASOA Annual Meeting  Associated Press

Press release *content* from Business Wire. The AP news staff was not involved in its creation.

Wet Age Related Macular Degeneration Market Analysis and Technology Advancement Outlook 2019 to 2026  The Edge

A new market study, titled “Discover Global Wet Age Related Macular Degeneration (AMD) Market Upcoming Trends, Growth Drivers and Challenges” has been ...

Allegro Ophthalmics Announces Positive Results of Ex-US Proof-of-Concept Trial with Integrin Inhibitor ALG-1007 for Dry Eye Disease  Associated Press

Press release *content* from Business Wire. The AP news staff was not involved in its creation.

Preclinical Studies Demonstrate Galimedix Therapeutics’ Investigational Compound GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Models  Yahoo Finance

Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today presented data demonstrating its novel, ...

7 Tips to Stop Macular Degeneration  Healthline

Macular degeneration is one of the leading causes of blindness in the United States. Here's how to keep your vision safe while enjoying the sun this spring ...

What Is Age-Related Macular Degeneration?  Next Avenue

Age-related macular degeneration (AMD) causes deterioration of the macula, the part of the eye that provides sharp, clear, straight-ahead vision. As many Here ...

Trial will be first in US of Nobel-winning stem cell technique  STAT

Curing diabetes with stem cells? Everyone knew that would be hard. Parkinson's disease? Harder. Alzheimer's? Probably impossible. But age-related macular ...

Visiongain Publishes Global Ophthalmic Equipment Market 2019-2029 Report  P&T Community

LONDON, May 20, 2019 /PRNewswire/ -- Global Ophthalmic Equipment Market by Product (Vision Care Products, Ophthalmology Surgical Devices and ...

How this woman was prevented from going completely blind  Stuff.co.nz

Wendy Johnstone got a huge shock when she realised she lost the sight in her left eye – she thought she just needed stronger glasses.

Metformin may offer protection against macular degeneration risk: JACC Study  Specialty Medical Dialogues

Commonly prescribed antidiabetic drug metformin may offer protection against the development of age-related macular degeneration (AMD), according to a ...

Allegro Ophthalmics Expands Its Anti-Integrin Portfolio with New Front-of-the-Eye Drug Candidate ALG-1007 for the Treatment of Dry Eye Disease  Yahoo Finance

Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular ...

Galimedix, Inc. Appoints Renowned Industry Veteran and Innovator in the Field of Ophthalmology Thomas Hohman, Ph.D. to Board of Directors  GlobeNewswire

KENSINGTON, Md. and SHORASHIM, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic ...

Breakthrough in identifying new genes in age-related macular degeneration, the leading cause of blindness  Medical Xpress

Fight for Sight funded research published this week in Clinical Epigenetics, has identified new genes linked to the development of age-related macular ...

33 Healthy Office Snacks to Keep You Energized and Productive  EcoWatch

Having nutritious snacks to eat during the workday can help you stay energized and productive. Still, coming up with ideas for snacks that are easy to prep, ...

Stealth BioTherapeutics (MITO) Reports Positive Results for Elamipretide in Ophthalmic Conditions  StreetInsider.com

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

American Academy of Opthalmology Suggests Tips for Healthy Eyes  NorthEndWaterfront.com

May is Vision Awareness Month. More than 20 million Americans suffer from severe vision loss. While not all eye diseases can be prevented, there are simple ...

Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis  P&T Community

LEXINGTON, Mass., May 20, 2019 /PRNewswire/ -- Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of ...

Take steps to prevent vision loss from macular degeneration  Buffalo News

By Judith Whitehead – Contributing Writer Age-related macular degeneration is the leading cause of blindness among older Americans but treatments have ...

Seeing clearly: Know your risk for macular degeneration  Baylor College of Medicine News

More than 60 million Americans are estimated to be at high risk for vision loss. However, according to the CDC, only half of those at risk have visited an eye ...

Human Trials Could Begin for Macular Degeneration Stem Cell Therapy  MD Magazine

FDA trial approval would make this trial the first ever to test a stem cell-based therapy derived from induced pluripotent stem cells for treating any disease.

What you need to know about wet macular degeneration Feb 14, 2019  Medical Xpress

Millions of people deal with age-related macular degeneration as they get older, but many don't understand the difference between types of the condition or ...

Eylea Approved for the Treatment of Diabetic Retinopathy  Monthly Prescribing Reference

The Food and Drug Administration (FDA) has approved Eylea (aflibercept; Regeneron) for the treatment of diabetic retinopathy. The approval of Eylea, ...

When was the last time you had an eye exam?  theperrynews.com

When was the last time you had an eye exam? If you have health insurance, it may cover this *service* and pay for all or part of the cost of eyeglasses. If you have ...

BioTime Reports First Quarter 2019 Financial Results and Provides Business Update  Business Wire

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, reported fi.

Age-Related Macular Degeneration: 5 Things to Know  Medscape

A guide to the latest on this chronic disease, from emerging treatments to the risk factors to be on the lookout for.

Age Related Macular Degeneration (AMD) Market – Detailed Analysis of Business Opportunities, Growth & Forecast to 2025: Key Players -Bayer, F. HoffmannLa Roche, Regeneron, Novartis  MajoReports

The latest release from HTF MI highlights the key market trends impacting the growth of the Global Age Related Macular Degeneration (AMD) market. The study ...

New Research On Wet Age Related Macular Degeneration (AMD) Market 2019-2024 | Net Profit, Sales, Revenue, And Growth Rate  Healthcare Reports

The research report published by Market.biz based on the Global Wet Age Related Macular Degeneration (AMD) Market Report 2019 aims to deliver an explicit ...

Treatment for Wet Age-Related Macular Degeneration Receives Biologics License Application Approval  Pharmacy Times

Officials with the FDA have accepted Novartis' Biologics License Application (BLA) for brolucizumab (RTH258), a humanized single-chain antibody fragment ...

5 questions: Breakthroughs in treatment for a common cause of vision loss among U.S. seniors  Philly.com

The standard treatment has been regular injections to the eyeball. So, not surprisingly, an active area of research has focused on finding alternatives, including ...

Stem Cell Therapy Patch for Macular Degeneration Sees the Light of Day  Genetic Engineering & Biotechnology News

If approved, the first ever clinical trail to test a stem cell-based therapy may provide a cure for age-related macular degeneration.

Macular degeneration treatment market size worth around US $11.4 billion by 2026: Acumen Research and Consulting  GlobeNewswire

LOS ANGELES, March 16, 2019 (GLOBE NEWSWIRE) -- The global macular degeneration treatment market size is anticipated to value USD 11.4 billion by ...

7 Healthy Habits to Help Prevent Macular Degeneration  University of Michigan Health System News

AMD affects the eyesight of millions. A Michigan Medicine specialist offers easy ways to help slow or prevent the disease.

Tiny eye device could make big difference for millions with blinding disease  Philly.com

Wills Eye Hospital has helped test an implantable delivery system for a widely used medication for age-related macular degeneration.

LumiThera receives $2.5 million grant to study dry AMD treatment option  Healio

LumiThera has received a $2.5 million small business innovative research phase II grant from the National Institute of Health and the National Eye Institute to ...

Age-related macular degeneration may be reduced by artificial intelligence  Health Europa

Action Against AMD have partnered with artificial intelligence company BenevolentAI to uncover the mysteries of age-related macular degeneration.

Global Gene Therapy for Age-related Macular Degeneration Market Report 2019 7ᵗʰ edition Top Companies, Sales, Revenue, Forecast and Detailed Analysis  The Market Research News

Gene Therapy for Age-related Macular Degeneration market report is based on present industry situations, market demands, business strategies utilized by ...

Revolutionary eye drops to treat age-related macular degeneration  Drug Target Review

Revolutionary eye drops to treat age-related macular degeneration - developing an eye drop that could revolutionise treatment for AMD.

Surgeons perform first gene therapy procedure aimed at stopping AMD-related blindness  Healio

Researchers have completed the first gene therapy procedure aimed at stopping age-related macular degeneration.The operation was performed at John ...

Be aware of age-related macular degeneration  thebellvillestar.com

COLUMBUS — Age-related macular degeneration (AMD), is a leading cause of vision loss for Americans age 50 and older. The eye disease causes damage to.

Fewer Injections With New Wet Macular Degeneration Therapies  Medscape

New treatments in development — including gene therapy — will likely mean fewer injections for patients with neovascular age-related macular degeneration, ...

Stem Cell Therapy Shows Early Promise Against Macular Degeneration  HealthDay

THURSDAY, Jan. 17, 2019 (HealthDay News) -- Age-related macular degeneration is the leading cause of vision loss in seniors, and existing treatments are few ...

Researchers home in on genes linked to age-related macular degeneration: Findings point to potential treatment strategies  Science Daily

Scientists have zeroed in on genes associated with age-related macular degeneration (AMD), a leading cause of vision loss and blindness among people age ...

LumiThera Announces First Patient Enrollment in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration  BioSpace

Published: Apr 11, 2019. SEATTLE, April 11, 2019 /PRNewswire/ -- LumiThera Inc., a commercial stage medical device company delivering photobiomodulation ...

Coherus BioSciences Inc. (CHRS)'s Financial Results Comparing With Osiris Therapeutics Inc. (NASDAQ:OSIR)  The EN Herald

As Biotechnology businesses, Coherus BioSciences Inc. (NASDAQ:CHRS) and Osiris Therapeutics Inc. (NASDAQ:OSIR), are affected by contrast.

BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)  Associated Press

Press release *content* from Globe Newswire. The AP news staff was not involved in its creation.

Global Juvenile Macular Degeneration Treatment Market 2019, Trend, CAGR Status, Growth, Analysis and Forecast to 2024  Asiancrunch

Researchunt has launched a *fresh* research report on Juvenile Macular Degeneration Treatment market. The study will help those involved in the sector since it ...

OpRegen shows positive phase 1/2a study results for dry AMD  Healio

CHICAGO — OpRegen, a retinal pigment epithelium cell therapy transplant for dry age-related macular degeneration, has shown signs of improving the retina ...

Eye Health Supplements Market Key Players: Alliance Pharma, Novartis AG, Amway Corp., Pfizer Inc.  New Daily Herald

Hectic lifestyles and exposure to toxic materials can adversely impact the eyesight of people, which is why they are compelled to strive for a healthy vision.

Gyroscope's gene therapy given to first dry AMD patient  PMLiVE

UK biotech Gyroscope Therapeutics could have a mass market product on its hands if its new gene therapy for one of the most common form of blindness proves ...

Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration  Science Advances

Choriocapillary loss is a major cause of neovascular age-related macular degeneration (NV-AMD). Although vascular endothelial growth factor (VEGF) blockade ...

Retinal Drugs And Biologics Market to Offer Lucrative Growth Prospects for Manufacturers by 2027 |ALLERGAN, Alimera Sciences  Wiki Times

Retina is a very sensitive and delicate part of human eye which is responsible for receiving and processing light to convert into neural signals and send to the ...

Benitec Biopharma Limited (BNTC) and Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) Comparison side by side  The EN Herald

Benitec Biopharma Limited (NASDAQ:BNTC) and Aeglea BioTherapeutics Inc. (NASDAQ:AGLE), both competing one another are Biotechnology companies.

AMD Monitoring Comes Home: The Promise of Remote Tech  Medscape

Age-related macular degeneration (AMD) is the leading cause of severe vision loss in older Americans. AMD is a degenerative disease that affects the macula, ...

Metformin for Macular Degeneration  Healthline

The popular diabetes medication, metformin, may soon be used not just to regulate blood sugar but to protect against a common form of blindness, called ...

Researchers discover new biomarker for age-related macular degeneration  Medical Xpress

Researchers from the University of Alabama at Birmingham Department of Ophthalmology and Visual Sciences, along with collaborators from the University of ...

Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Insights 2019 - Industry Overview, Competitive Players & Forecast 2025  Healthcare Reports

The report titled “Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market” gives a proper understanding of global Juvenile Macular ...

7 Macular Degeneration Risk Factors You Can Control—and 4 You Can't  Reader's Digest

Your chances of getting this top cause of vision loss in people age 60 and older—depends on both your genetics and your lifestyle.

Wet Macular Degeneration Market Forecast, Size, Strategies, Trends, Key Manufacturers and SWOT Analysis 2024  Speaking Times

Wet Macular Degeneration Market report covers the disease overview, definition, classification, symptoms, ethology, pathophysiology and diagnostic methods.

Gene Therapy for the Most Common Form of Blindness Gets Its First Human Test  Gizmodo

An 80-year-old woman from the United Kingdom is the first patient to undergo gene therapy to treat age-related macular degeneration—the most common cause ...

Has UVa Found a Cure for Macular Degeneration?  WMRA Public Radio

Macular degeneration is the leading cause of vision loss, affecting two million Americans over 40, with 7 million more at risk of developing the disease.

Market Study: Ophthalmology Drugs & Devices Market Anticipated to Reach $36.95. billion by 2025 | A report by Carl Zeiss Meditec AG, Alcon Inc, Johnson & Johnson, Topcon Corporation, Nidek, Haag-Streit Group and others  Market Trends

Ophthalmic medical devices are the devices which are used in the treatment of eye related ailments through drugs or through devices. The devices used in the ...

Outlook Therapeutics Provides Business Update and Reports Second Quarter Financial Results for Fiscal 2019  Yahoo Finance

CRANBURY, N.J., May 15, 2019 -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported business highlights and financial results for its ...

Hope for new macular degeneration treatments buoys patients  The Boston Globe

Sean Teare, a 48-year-old health care consultant from Duxbury, struggled to read menus in dimly lit restaurants. After a battery of tests, his optometrist told him ...

New Research On Juvenile Macular Degeneration (Stargardt Disease) Treatment Market 2019-2024 | Net Profit, Sales, Revenue, And Growth Rate  Healthcare Reports

The research report published by Market.biz based on the Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Report 2019 aims to ...

BioTime, Orbit Biomedical to collaborate on OpRegen subretinal delivery for dry AMD  Healio

BioTime has entered into a research and option agreement with Orbit Biomedical regarding technology to deliver OpRegen to treat dry age-related macular ...

Gemini to initiate CLARITY dry AMD disease registry and study  Healio

Gemini Therapeutics announced a disease registry and natural history study to identify and characterize disease progression in patients with non-central ...

Lutronic Vision Engages World Renowned Retina Expert for R:GEN™ Pilot AMD Clinical Study  Associated Press

Press release *content* from Globe Newswire. The AP news staff was not involved in its creation.

BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)  Associated Press

Press release *content* from Business Wire. The AP news staff was not involved in its creation.

How to spot age-related macular degeneration  The Guardian

Every day in the UK, nearly 200 people develop a condition that can lead to visual impairment or even blindness. How do you identify the symptoms and what's ...

Drug Slows Atrophy in Dry AMD | Medpage Today  MedPage Today

No vision improvement with complement C3 inhibitor.

Global Ophthalmic Drugs Market || Size, Share, Emerging Trends & Influence Factors 2019-2027 - All  Marketing Strategy

The analysis establishes the Ophthalmic Drugs fundamentals: definitions, classifications, software and Ophthalmic Drugs market review; product specifications; ...

Researchers are one step closer to developing eye drops to treat age-related macular degeneration  Medical Xpress

Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration ...

» Load more

What about Resources?

Dr. Pautler's Blog
American Academy of Ophthalmology
MedlinePlus
National Institutes of Health
  • ARMD
    NIH's SeniorHealth website covers the topic of Age-Related Macular Degeneration
National Eye Institute
American Foundation for the Blind - Senior Site
  • Macular Degeneration
    Basic information about AMD and low vision; includes a self-test using an Amsler Grid
Journal of the American Medical Association (JAMA)
WebMD
LightHouse International
  • Macular Degeneration
    Provides a general overview of the basics of AMD, and a simulation showing a scene as it might be viewed by a person with AMD
Prevent Blindness America